Advancements in the Management of R/R AML: ASH 2024 - Episode 8
Integrating Revumenib Into Current R/R AML Treatment Paradigms
Panelists discuss key findings from the phase I/II study of the all-oral SAVE combination with revumenib in relapsed/refractory acute monocytic leukemia (R/R AML), the impact of the regimen's success in achieving high response and MRD negativity rates on integrating all-oral therapies into the treatment paradigm for R/R AML, particularly in patients with prior venetoclax or transplant exposure, and the potential role of revumenib in current treatment paradigms for R/R AML.
Video Player is loading.
Video content above is prompted by the following:
- Dr. LeBlanc to ask Dr. Goldberg: Briefly comment on the key findings presented from the Pphase I/II study of the all-oral “SAVE” combination with revumenib in R/R AML.(Issa, GC, et al. ASH 2024. Oral Abstract 216, Session: 616 or pg. 13)
- Dr. LeBlanc to ask Dr. Blachly: How does the success of the SAVE regimen in achieving high response and MRD negativity rates influence the integration of all-oral therapies into the treatment paradigm for R/R AML, particularly in patient populations with prior venetoclax or transplant exposure?
- Dr. LeBlanc to ask GROUP: Where do you see revumenib fitting in your current treatment paradigms for R/R AML?
Related Content:
